Drugs Rules 1945 Amendment 2026: Rule 89 Update on Form 29 Licensing

Drugs Rules 1945 Amendment 2026: Rule 89 Update on Form 29 Licensing

Introduction

The Government of India has issued a draft notification (G.S.R. 299(E) dated 21 April 2026) proposing amendments to the Drugs Rules, 1945. The update focuses on Rule 89, specifically addressing licensing requirements under Form 29 for different categories of drug manufacturing.

The proposal has been released by the Ministry of Health and Family Welfare in consultation with the Drugs Technical Advisory Board (DTAB), reflecting a structured regulatory approach.

What is the Drugs Rules 1945 Amendment 2026 About?

The Drugs Rules 1945 amendment 2026 introduces a revision to the wording under Rule 89, expanding the scope of licensing forms applicable for obtaining permission through Form 29 license in India.

This proposed change ensures that multiple categories of drug manufacturing licenses are appropriately covered within the regulatory framework, improving clarity and alignment with existing licensing practices.

Key Change Under Rule 89

Under the existing provision, the reference is limited to:

• Form 25

• Form 28

Proposed Amendment

The draft notification expands this list to include:

• Form 25

• Form 25A

• Form 25F

• Form 28

• Form 28A

• Form 28B

• Form 28D

• Form 28DA

• Form 28F

This update reflects a broader and more structured approach to drug manufacturing license categories in India, ensuring better regulatory coverage.

Why This Amendment Matters

The proposed amendment is relevant for stakeholders involved in:

• Pharmaceutical manufacturing

• Drug licensing and compliance

• Regulatory approvals in India

By incorporating additional license forms, the update strengthens the Form 29 licensing framework and supports a more comprehensive regulatory system.

Regulatory Process and Timeline

The draft has been published for public consultation, allowing stakeholders to submit:

• Objections

• Suggestions

within 30 days from its publication in the Gazette.

After finalization, the amended provisions will come into effect three months after publication in the Official Gazette, ensuring sufficient transition time.

Legal Framework

This amendment is proposed under the provisions of the Drugs and Cosmetics Act, 1940, which governs drug regulation and licensing in India.

It also reflects ongoing efforts to enhance the pharmaceutical regulatory framework in India, making licensing provisions more inclusive and clearly defined.

Conclusion

The Drugs Rules 1945 amendment 2026 introduces an important update to Rule 89, expanding the list of applicable license forms for permissions under Form 29.

This revision supports improved alignment of drug manufacturing licenses in India with evolving regulatory requirements, contributing to a more structured and accessible compliance framework.

FAQs 

What is Rule 89 of Drugs Rules 1945?

Rule 89 outlines the permissions required for certain categories of drug manufacturing, including those obtained through Form 29.

What is Form 29 license in India?

Form 29 is used to obtain permission for manufacturing drugs for examination, testing, or analysis under specific regulatory conditions.

What is the key change in the 2026 amendment?

The amendment expands the list of license forms under Rule 89 to include Forms 25A, 25F, 28A, 28B, 28D, 28DA, and 28F.

Access the official document for complete details

Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well. May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.